While the use of chimeric antigen receptor (CAR) T-cell therapy has increased ... The most frequent of these immune-mediated ...

在在这项最新研究中，研究团队通过模拟异种移植组织排斥过程中快速且强烈的抗原加工和呈递，可利用暴露组织特异性抗体的异种细胞膜来源的囊泡将多肽抗原和 mRNA 编码抗原递送至树突状细胞（DC）。 在 黑色素 瘤小鼠和 胸腺瘤 ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Our patients, they get CAR-T cells either in the hospital or outpatient. So, we either admit the patient for about 10 days, we give them the cells, you know, on the first day, their own cells. And ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Five patients had mild cytokine release syndrome that was effectively treated, and two patients experienced cystitis, which is irritation of the bladder. Unfortunately, the CAR-T cells did not ...

Think of it this way — the human body is a kingdom which is healthy, prosperous and functions peacefully. Every once in a while, invaders from the pat ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...